Every research question we ask begins with a simple goal: improving life for patients. At Celltrion, we look ahead—anticipating tomorrow’s challenges in healthcare and investing today in the science that can solve them.
We are one of the few fully integrated biopharmaceutical companies with seamless capabilities that span the entire development journey.
Discovery &
design:
Advancing new biologic candidates and biosimilars using proprietary cell line and formulation platforms.
Preclinical & clinical development:
Running global-scale trials with proven regulatory expertise across the US, Europe, and Asia.
Manufacturing & scale‑up:
Translating breakthroughs from lab to large-scale, FDA- and EMA-approved facilities.
Commercialization & access:
Ensuring therapies reach patients in more than 100 countries with consistent quality and supply.
Celltrion developed the world’s first monoclonal antibody biosimilar, proving that advanced biologic medicines could be made more accessible to patients without compromising safety or efficacy. Our biosimilars continue to broaden access to high-quality therapies worldwide—helping healthcare systems save costs and patients receive care sooner.
Beyond biosimilars, we are developing novel biologics designed to address previously unmet medical needs:
Next-generation antibodies, including bispecific and multispecific platforms that enhance tumor selectivity and safety.
Antibody-drug conjugates (ADCs), engineered with dual payloads and bystander effects for cancer-fighting potential.
Our proprietary platforms accelerate development and help improve patient care:
Cell line platform – optimized for stability, productivity, and speed to clinic.
Advanced formulations – high-concentration solutions that improve shelf stability and make convenient treatments for patients.
Microbiome therapeutics that harness the power of the gut microbiota intended to treat complex immune and inflammatory diseases.
Research is more than science—it's a promise. Every therapy we advance, every platform we refine, every trial we launch is driven by a single conviction: that better science today means better care tomorrow.